This durability of the response is currently explained by the theoretical rationale that anti–PD-L1 therapy can generate a mono or polyclonal and memory adaptive T-cells anti-tumor immunity, either CD45 or CD86 that is able to control the heterogeneity of the disease and to reset the tumor-host immune interaction toward cancer rejection [5]. This evidence concerns the gene PTPRC and neoplasm.